"10.1371_journal.pone.0011504","plos one","2010-07-09T00:00:00Z","Federico C F Calboli; Federica Tozzi; Nicholas W Galwey; Athos Antoniades; Vincent Mooser; Martin Preisig; Peter Vollenweider; Dawn Waterworth; Gerard Waeber; Michael R Johnson; Pierandrea Muglia; David J Balding","Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom; Genetics Division, Drug Discovery, GlaxoSmithKline R&D, Verona, Italy; Discovery Biometrics Respiratory, GlaxoSmithKline, Greenford, United Kingdom; Department of Computer Science, University of Cyprus, Nicosia, Cyprus; Genetics Division, Drug Discovery, GlaxoSmithKline R&D, Upper Merion, Pennsylvania, United States of America; Department of Psychiatry, University Hospital Center and University of Lausanne, Lausanne, Switzerland; Department of Internal Medicine, University Hospital Center and University of Lausanne, Lausanne, Switzerland; Department of Clinical Neurosciences, Imperial College London, London, United Kingdom; Discovery Medicine, Neurosciences CEDD, GlaxoSmithKline R&D, Verona, Italy; Genetics Institute, University College London, London, United Kingdom","Conceived and designed the experiments: FCFC FT NWG MJ PM DB. Wrote the paper: FCFC FT NWG MJ DB. Contributed to data analysis and manuscript writing: AA. Contributed to the design of the population based study and to the writing of the manuscript: VM. Conceived the design of the population based study: MP PV GW. Principal Investigators of the study: MP PV GW. Contributed to the design of the current study and critically reviewed the manuscript: MP PV GW. Contributed to the design of the population based study and critically reviewed the manuscript: DW. Supervised the work and contributed with a critical review of the manuscript: PM DB.","F. Tozzi, V. Mooser, D. Waterworth and N. W. Galwey are GlaxoSmithKline (GSK) full-time employees. P. Muglia was a GlaxoSmithKline full-time employee at the time when this study was performed. M. Johnson was a GSK consultant at the time when the project was initiated. F. Calboli was supported by a GSK grant to Imperial College London. The PsyCoLaus study was supported by grants from the Swiss National Science Foundation (#3200B0-105993, #3200B0-118308, 33CSCO-122661) and from GlaxoSmithKline (Psychiatry Center of Excellence for Drug Discovery and Genetics Division, Drug Discovery - Verona, R&D). GSKs role does not alter the authors adherence to the PLoS ONE policies on sharing data.","2010","07","Federico C F Calboli","FCFC",12,TRUE,6,NA,NA,5,TRUE,FALSE,FALSE,0,NA,FALSE
